title: Performance of amplified DNA in an Illumina GoldenGate BeadArray assay.
abstract: Whole genome amplification (WGA) offers a means to enrich DNA quantities for epidemiologic studies. We used an ovarian cancer study of 1,536 single nucleotide polymorphisms (SNPs) and 2,368 samples to assess performance of multiple displacement amplification (MDA) WGA using an Illumina GoldenGate BeadArray. Initial screening revealed successful genotyping for 93.4% of WGA samples and 99.3% of genomic samples, and 93.2% of SNPs for WGA samples and 96.3% of SNPs for genomic samples. SNP failure was predicted by Illumina-provided designability rank, %GC (P < or = 0.002), and for WGA only, distance to telomere and Illumina-provided SNP score (P < or = 0.002). Distance to telomere and %GC were highly correlated; adjustment for %GC removed the association between distance to telomere and SNP failure. Although universally high, per-SNP call rates were related to designability rank, SNP score, %GC, minor allele frequency, distance to telomere (P < or = 0.01), and, for WGA only, Illumina-provided validation class (P < 0.001). We found excellent concordance generally (>99.0%) among 124 WGA:genomic replicates, 15 WGA replicates, 88 replicate aliquots of the same WGA preparation, and 25 genomic replicates. Where there was discordance, it was across WGA:genomic replicates but limited to only a few samples among other replicates suggesting the introduction of error. Designability rank and SNP score correlated with WGA:genomic concordance (P < 0.001). In summary, use of MDA WGA DNA is feasible; however, caution is warranted regarding SNP selection and analysis. We recommend that biological SNP characteristics, notably distance to telomere and GC content (<50% GC recommended), as well as Illumina-provided metrics be considered in the creation of GoldenGate assays using MDA WGA DNA.
authors.affiliation: Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: Julie M
authors.initials: JM
authors.lastname: Cunningham
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Sellers
authors.forename: Joellen M
authors.initials: JM
authors.lastname: Schildkraut
authors.forename: Zachary S
authors.initials: ZS
authors.lastname: Fredericksen
authors.forename: Robert A
authors.initials: RA
authors.lastname: Vierkant
authors.forename: Linda E
authors.initials: LE
authors.lastname: Kelemen
authors.forename: Madhura
authors.initials: M
authors.lastname: Gadre
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Phelan
authors.forename: Yifan
authors.initials: Y
authors.lastname: Huang
authors.forename: Jeffrey G
authors.initials: JG
authors.lastname: Meyer
authors.forename: V Shane
authors.initials: VS
authors.lastname: Pankratz
authors.forename: Ellen L
authors.initials: EL
authors.lastname: Goode
mesh_terms: D000416:Alberta / Q000453:epidemiology; D014408:Biomarkers, Tumor / Q000235:genetics*; D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D005838:Genotype; D006801:Humans; D018189:Immunomagnetic Separation / Q000379:methods*; D015994:Incidence; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000235:genetics*; D015203:Reproducibility of Results; D014481:United States / Q000453:epidemiology
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm